NewsRoom Articles - BioMedWire (BMW)

ThursdayMar 26, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials These developments position the company at the intersection of innovation and therapeutics Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side…

ThursdayMar 26, 2026 10:00 am

Hackers Linked to Iran Target Another US Health Care Institution

On Tuesday this week, researchers revealed that a group of hackers linked to the Iranian government had targeted another United States medical institution toward the end of February prior to the onset of the current military conflict between the U.S., Israel and Iran. This is the second such attack. This attack is noteworthy because this information comes on the heels of another attack in which Stryker, a medical device firm in America, was targeted and had its data deleted. Handala, a hacktivist group linked to Iran, claimed responsibility for this attack that resulted in about 80,000 systems being deleted. Stryker is currently restoring its systems and the attack has now been contained. It isn’t clear whether other attacks have happened…

ThursdayMar 26, 2026 9:00 am

Earth Science Tech Inc. (ETST) Builds Integrated Healthcare Platform for Scalable Growth

ETST is focused on compounding pharmacies, telemedicine, and clinical services Vertically integrated model supports recurring, patient-driven revenue The company’s strategy aligns with increased demand for personalized and digital healthcare Earth Science Tech (OTC: ETST) is consolidating on its identity as a leading healthcare holding company, implementing a strategy built on vertical integration across telemedicine, pharmaceuticals, and clinical services. The company’s transitioning from legacy operations highlights a distinct alignment with high-growth segments of the healthcare sector, particularly personalized medicine and digital care delivery (ibn.fm/9lMJg). At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific…

TuesdayMar 24, 2026 11:15 am

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology…

TuesdayMar 24, 2026 10:00 am

Misinformation Could Thwart the Potential of Cancer Vaccines

For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is being registered in developing mRNA vaccines against cancer, but this progress has come up against a wall of misinformation that could thwart the prospects of this promising intervention. Most people first heard about mRNA vaccines during the Covid-19 pandemic when these vaccines were widely used to bring the pandemic under control. However, misinformation soon spread that these vaccines were not only accelerating cancer rates but also causing cancer to be “turbo-charged.” Social media was awash with stories of “turbo cancer” starting in 2021 and mainstream media caught…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…

TuesdayMar 24, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL. Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning…

FridayMar 20, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs. The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease. The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide. Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet…

FridayMar 20, 2026 10:00 am

Oncolytic Virus Therapy is Set to Transform Cancer Care

Enormous resources are being channeled into studying different ways to support the immune system in its fight against cancer. One emerging approach is the use of oncolytic viruses. This approach seeks to leverage viruses to destroy cancer by attacking and killing its cells. The approach stems from the discovery that a number of cancers are linked to viral infections, such as HPV, which has been linked to the development of head and neck cancer, as well as cervical cancer. Liver cancer has also been linked to the hepatitis B virus. A number of vaccines have been developed to prevent some of these cancers by preventing infection by these viruses. Scientists are now looking to go a step further by…

FridayMar 20, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within this evolving scientific landscape, LIXTE Biotechnology is pursuing a strategy designed to improve the performance of existing cancer treatments. Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells. Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy with chemotherapy to help the immune system better recognize and attack tumors. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Hackers Linked to Iran Target Another US Health Care Institution

Earth Science Tech Inc. (ETST) Builds Integrated Healthcare Platform for Scalable Growth

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

Misinformation Could Thwart the Potential of Cancer Vaccines

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Oncolytic Virus Therapy is Set to Transform Cancer Care

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search